Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Clinical trial NCT02822495 · NO_LONGER_AVAILABLE

Trial details

NCT number: NCT02822495
Sponsor: Atara Biotherapeutics
Status: NO_LONGER_AVAILABLE
Study type: EXPANDED_ACCESS

Epstein-Barr Virus (EBV) Infections Lymphoproliferative Disorders EBV+ Associated Lymphoma EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Epstein-Barr Viremia Lymphoma, AIDS-related Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID)Leiomyosarcoma (LMS)Nasopharyngeal Carcinoma (NPC)Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID)Solid Organ Transplant Complications Stem Cell Transplant Complications

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.